- IP and COVID—part of the solution not part of the problem
- First of all, it doesn’t fix the problem
- So what can be done to continue to increase capacity and achieve what we all want—more doses to more people, more quickly?
Life Sciences analysis: Witnessing millions of Europeans getting their vaccines just 12 months on from the first discovery of coronavirus (COVID-19), is an incredible collaborative, scientific, manufacturing and logistical achievement involving the global research community working in lockstep with the research-based pharmaceutical industry, EU institutions, governments, regulators and health-systems. Nathalie Moll, director general at European Federation of Pharmaceutical Industries and Associations, discusses the R&D and manufacturing challenges posed by the pandemic.
Sign in or take a trial to read the full analysis.
To continue reading this news article, as well as thousands of others like it, sign in to LexisPSL or register for a free trial